Drugs.com - New Drug Approvals

FDA Approves Alhemo (concizumab-mtci) to Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors

PLAINSBORO, N.J., Dec. 20, 2024 /PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding...

Feb 9, 2025 - 22:25
 0
FDA Approves Alhemo (concizumab-mtci) to Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors
PLAINSBORO, N.J., Dec. 20, 2024 /PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding...
Read More

Tags:

Previous Article

FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine ...

Next Article

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree (setmelanotide) for Pa...

Related Posts

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

FDA Approves Journavx (suzetrigine), a First-in-Class T...

Feb 9, 2025  0

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer

FDA Grants Accelerated Approval to Bizengri (zenocutuzu...

Feb 9, 2025  0